JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.14 4.59

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.1400000000000001

Máximo

1.15

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Recomendaciones
By TipRanks
Recomendaciones	Vender
Estimación a 12 Meses	+250.88% upside

Dividendos
By Dow Jones
Próximas Ganancias	26 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-29M 73M
Apertura anterior	-3.45
Cierre anterior	1.14

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 feb 2026, 09:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

7 feb 2026, 09:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 feb 2026, 05:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 feb 2026, 02:46 UTC

Adquisiciones, fusiones, absorciones

Big Money, High Anxiety -- Barrons.com

6 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 feb 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

6 feb 2026, 21:40 UTC

Adquisiciones, fusiones, absorciones

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 feb 2026, 21:22 UTC

Charlas de Mercado

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 feb 2026, 21:17 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 21:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 feb 2026, 21:14 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 feb 2026, 21:13 UTC

Ganancias

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 feb 2026, 21:13 UTC

Ganancias

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 feb 2026, 21:04 UTC

Charlas de Mercado

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 feb 2026, 20:34 UTC

Ganancias

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

6 feb 2026, 20:27 UTC

Ganancias

These Stocks Are Today's Movers: Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More -- Barrons.com

6 feb 2026, 20:24 UTC

Charlas de Mercado

Oil Futures Settle Higher As U.S.-Iran Talks Get Under Way -- Market Talk

6 feb 2026, 20:20 UTC

Charlas de Mercado

U.S. Natural Gas Futures Retreat Ahead of Weekend -- Market Talk

6 feb 2026, 19:48 UTC

Ganancias

Take-Two, Mondelez Get Analyst Attention -- Barrons.com

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

Justice Department Asking Industry How Netflix or Paramount Deal for Warner Bros. Might Impact Competition, According to Subpoena -- WSJ

6 feb 2026, 19:30 UTC

Adquisiciones, fusiones, absorciones

DOJ Asking if Netflix Engaged in 'Exclusionary Conduct' That May Lead to Monopoly, According to Subpoena -- WSJ

6 feb 2026, 19:17 UTC

Charlas de Mercado

USDA Says Farm Income to Decrease in 2026 -- Market Talk

6 feb 2026, 18:50 UTC

Ganancias

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 feb 2026, 18:47 UTC

Charlas de Mercado

Natural Gas-Infrastructure Operators Take 'Flight to Scale' -- Market Talk

6 feb 2026, 18:34 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 1 to 412 -- Market Talk

6 feb 2026, 17:58 UTC

Ganancias

Reddit Stock Falls After Strong Earnings. Wall Street Is Debating What's Next. -- Barrons.com

6 feb 2026, 17:52 UTC

Charlas de Mercado

Ganancias

Global Equities Roundup: Market Talk

6 feb 2026, 17:52 UTC

Charlas de Mercado

Ganancias

Amazon's CapEx Seen as Misunderstood by Investors -- Market Talk

6 feb 2026, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

250.88% repunte

Estimación a 12 Meses

Media 4 USD 250.88%

Máximo 4 USD

Mínimo 4 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Vender

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.